7:10 am Morning Check-In: Served with coffee + light breakfast
8:10 am Chair’s Opening Remarks
8:15 am Keynote: Shaping The Future of Skin Therapeutics: Clinical Momentum & Strategic Innovation
Synopsis
- Evaluating progress in dermatological therapies by reviewing approved products and late-stage clinical assets in conditions like acne, atopic dermatitis, and psoriasis
- Exploring market potential in underserved segments of dermatology, including paediatric patients, rare inflammatory diseases, and post-biologic maintenance strategies
- Evaluating tools with the most promise for the future: from AI, synthetic biology platforms, and scalable topical manufacturing to unlock next-gen innovations
Pioneering The Next Generation Of Dermatology Innovation Through Mechanistic Precision, Digital Disruption & Deeper Disease Understanding
8:45 am SCARLETRED AI for Next-Gen Dermatology Research: Blending Human Intuition with Machine Learning Precision
Synopsis
- Standardized, high-resolution mobile imaging for consistent and scalable data capture across clinical sites
- Smart Image analysis powered by objective data and machine learning in Psoriasis, Hidradenitis Suppurativa, and other inflammatory skin diseases
- Real-time AI-driven decision support tools to enhance clinical trial design and execution
- Development of digital biomarkers and novel endpoints to accelerate treatment validation in clinical R&D and post-marketing studies
9:15 am Advancing Precision Depigmentation Through Real-World Learnings in Vitiligo
Synopsis
- Key outcomes and safety insights from adult and adolescent trials investigating topical JAK inhibition in vitiligo
- Translating clinical success to pediatric populations and adapting protocols for less extensive disease
- Navigating operational and regulatory challenges including enrollment barriers and long-term data expectations
- Applying lessons from atopic dermatitis programs to improve trial design, endpoint strategy, and FDA alignment in vitiligo
9:45 am Speed Networking
Synopsis
A prime chance to make the most of in-person networking, and forge new connections as new
companies enter and existing ones broaden their presence within the dermatology space.
Designed to maximize your introduction to numerous new individuals and serve as a catalyst for
ongoing discussions during the summit.
10:15 am Morning Break & Refreshments
Advancing Precision Dermatology Through Multi-Omic Profiling, Digital Imaging, And Microbiome-Driven Therapies
10:45 am Modulating Microbial Behaviors to Treat Skin Disease: ENS-002 in Atopic Dermatitis & 33 Million Data Points for Targeted Microbial Interventions
Synopsis
- Discover how Concerto’s kChip platform identified ENS‑002 by screening over 5 million microbial combinations
- Highlight the Phase I trial testing ENS‑002’s safety and impact on Staphylococcus aureus in AD patients
- Explore how microbe-based therapies like ENS‑002 can provide long-term relief without the risks of immunosuppression
- Preview the Skin Universe Project’s role in enabling future microbial consortia for other dermatologic conditions
11:15 am Novel Imaging Endpoints: Redefining Objectivity in Dermatology Clinical Trials
Synopsis
- Automatic detection and segmentation of vitiligo
- 3D photography as a way to quantify dermatologic conditions
- Artificial Intelligence: automatic scoring of acne severity
11:30 am Roundtable Discussion: Overcoming Cell Sourcing Challenges to Advance Translational & Preclinical Dermatology Research
Synopsis
- Evaluating primary human keratinocytes and fibroblasts versus immortalized or stem cell‑derived lines for disease modeling
- Addressing variability and reproducibility across donor-derived cells and commercial suppliers
- Optimizing sourcing strategies for rare or inflamed patient-derived skin samples in inflammatory and autoimmune indications
- Integrating 3D skin models and organoids with well-characterized cell populations to improve translational relevance
12:00 pm Lunch & Learn: Hosted by Premier Research
Synopsis
Invitation only session hosted by Premier Research. For all other attendees, lunch is provided in the exhibition area.
Charting The Future Of Dermatology R&D: Emerging Science, Novel Modalities & Translational Breakthroughs In Inflammatory Skin Disease
1:00 pm Roundtable Discussion: How Can Patient-Derived Cells and High- Throughput Models Advance Our Understanding of Skin Disease Heterogeneity?
Synopsis
- Exploring the use of patient-derived cells to better model individual variability driven by genetics, microenvironment, and environmental triggers
- Using simple cell-based assays to screen therapeutic candidates before moving into more complex, tissue-like co-culture systems
- Investigating how inflammatory cytokines and molecular signals can be layered into co-cultures to mimic lesion-specific disease states
- Understanding the importance of recapitulating 3D skin architecture to accurately predict treatment efficacy in heterogeneous patient populations
1:30 pm Targeting the Inflammasome to Treat Chronic Inflammatory Skin Diseases: Clinical & Preclinical Advances in Atopic Dermatitis and Alopecia Areata
Synopsis
- Presenting Phase 2 clinical trial data demonstrating the efficacy and safety of a novel inflammasome inhibitor targeting GPCR19 in patients with mild-to-moderate atopic dermatitis
- Highlighting preclinical results in canine models using oral formulation showing potent suppression of NLRP3 inflammasome activation, supporting the development of 2nd generation compounds.
- Sharing early-stage data in alopecia areata showing restoration of hair growth through immune modulation, including inflammasome inhibition and upregulation of regulatory T cells by 2nd generation GPCR19 agonist
- Exploring a dual-acting mechanism that combines inhibition of inflammasome assembly and cytokine signalling as a differentiated strategy for long-term control of chronic skin inflammation such as rosacea and acne
2:00 pm Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue
forging new and beneficial relationships. With an audience of preclinical, translational, and clinical
scientists eager to hear the latest advancements in dermatology therapeutic development, you will
have the opportunity to display a poster presenting your own work and innovations.
2:30 pm Afternoon Break & Refreshments
Precision Immunomodulation, Targeted Innovation & Rethinking Route Of Delivery For The Next Generation Of Skin Therapies
3:00 pm Harnessing Immunomodulation to Transform Atopic Dermatitis & Beyond
Synopsis
- Immune mediation may result in complex dermatologic pathologies
- Immunomodulating, specifically focusing on T cells, may positively contribute to disease management
- Targeting the OX40 pathway in dermatology, eg atopic dermatitis, may result in sustained changes, representing remission (with case studies)
- Designing biologics with extended dosing intervals and low immunogenicity to reduce treatment burden and improve adherence
- Translational strategies are able to bridge mechanistic understanding to clinic-ready molecules that balance potency, safety, and patient convenience
3:30 pm Panel Discussion: Can Topical and Systemic Therapies Each Find Their Place in the Future of Dermatology Drug Development?
Synopsis
- How should we balance the clinical and commercial drivers behind topical and systemic innovation, especially as realworld prescribing habits continue to favor topicals? How are these approaches viewed from the patient, regulator and investor perspective?
- Which factors, including disease severity, body surface area, and treatment setting, best guide whether a topical, systemic, or combination approach is most appropriate? How can we best utilize both routes to ensure there is a treatment fit for everyone?
- How are both approaches evolving to better meet patient needs, from systemics tackling severe or widespread disease to topicals aiming for convenience, safety, or even disease modification?
- What are the key trade-offs between topical and systemic treatments in terms of patient adherence, cost, quality of life, and long-term disease control and how can trials be designed to reflect this?